Peptides: Peter Attia's Framework for Separating Science from Marketing

Most people interested in peptides are looking for the same thing: a signal buried under layers of gym lore, supplement marketing, and forum testimonials. Peter Attia’s episode #403 is the clearest framework for finding it.

Why Everyone Believes This

The gray-market peptide category is enormous precisely because the marketing is sophisticated. BPC-157, CJC-1295, and dozens of similar compounds circulate through fitness and longevity communities with elaborate mechanistic explanations — VEGF upregulation, GH axis stimulation, nitric oxide modulation. The vocabulary sounds like clinical literature. Doctors prescribe them. Compounding pharmacies make them. The entire apparatus of legitimate medicine appears to be in place.

That’s the trap Attia identifies: the infrastructure of legitimacy — prescriptions, purity testing, legitimate-sounding mechanisms — is not the same as evidence of benefit.

What the Evidence Shows

Attia introduces a three-bucket classification and a five-question test that cuts through the noise.

The three buckets:

• Bucket 1: No validated mechanism, no credible human evidence (BPC-157 lands here)
• Bucket 2: Biologically plausible but no clinical proof of human benefit (CJC-1295)
• Bucket 3: Scientifically legitimate with demonstrated human efficacy (GLP-1 agonists, tesamorelin)

The five questions applied to any peptide:

1. Is there a viable mechanism of action in humans?
2. Is there meaningful evidence of human benefit from controlled trials?
3. Are dosing, pharmacokinetics, and safety understood?
4. Does the benefit justify the risk, given what’s unknown?
5. Is there a better-characterized alternative?

BPC-157’s track record illustrates how badly the gray market fails this screen: “Three decades, dozens of fantastical benefits, and not a single human RCT.” Its claimed mechanisms — VEGF, angiogenesis, nitric oxide pathways — are unestablished in humans. Its parent protein has never been fully characterized. Dosing protocols are, in Attia’s word, “essentially guesses.”

The tells of illegitimate science compound this: where real drug development narrows indications over time as evidence accumulates, BPC-157’s claimed benefits have only expanded — from wound healing to gut health to neurological protection — while the foundational evidence remained absent. That’s the opposite trajectory of a legitimate pharmaceutical.

CJC-1295 represents a subtler failure. The biology is real — it does raise growth hormone and IGF-1. But raising a biomarker is not the same as improving an outcome. Direct growth hormone administration in adults with normal levels produces “surprisingly underwhelming” functional results; lean mass increases often reflect water retention rather than functional muscle.

The Correction

The rational framework for healthy individuals is straightforward: the evidence threshold should be higher, not lower, when speculative benefits are the goal. Patients with life-limiting conditions can rationally accept more uncertainty. Healthy people chasing marginal performance gains cannot. As Attia summarizes: “Peptides as a class can be genuinely powerful, which is a reason to be more careful with them, not less.”

This applies to testimonials too. When recovery improves after starting BPC-157, most people are also training better, sleeping more, reducing other stressors. Anecdote cannot separate the molecule from the ritual.

Source: Peter Attia MD

Content created with AI assistance and reviewed for accuracy.